nach oben

Erschienen in:

14.08.2017 | SSAT State-of-the-Art Conference

SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors

verfasst von: Jeffrey A. Norton, Teresa Kim, Joseph Kim, Martin D. McCarter, Kaitlyn J. Kelly, Joyce Wong, Jason K. Sicklick

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The current era of gastric surgery is marked by low morbidity and mortality rates, innovative strategies to approach resections with a minimally invasive fashion or hyperthermic intraperitoneal chemotherapy (HIPEC), as well as improved understanding of the biology of sporadic and hereditary stromal, neuroendocrine, and epithelial malignancies.

Methods

In 2017, the Society for Surgery of the Alimentary Tract convened a State-of-the-Art Conference on Current Surgical Management of Gastric Tumors with both international experts and emerging leaders in the field of gastric surgery.

Results

Martin D. McCarter, MD of the University of Colorado discussed the current management of gastric gastrointestinal stromal tumors (GIST). Kaitlyn J. Kelly, MD of the University of California, San Diego discussed the management of gastric carcinoid tumors. Jeffrey A. Norton of Stanford University discussed recent advances in the management of gastric adenocarcinoma including a focus on hereditary diffuse gastric cancer (HDGC). Joseph Kim, MD of Stony Brook University discussed a systematic approach to minimally invasive gastrectomy for cancer. Joyce Wong, MD of Pennsylvania State University discussed the role for cytoreductive surgery (CRS) and HIPEC for gastric adenocarcinoma.

Conclusions

This review provides gastrointestinal surgeons with a concise update on the current surgical management of gastric tumors.

Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annual Review of Medicine. 2012;63:247–58. doi:10.1146/annurev-med-043010-091813.CrossRefPubMed

Keung EZ, Raut CP. Management of gastrointestinal stromal tumors. The Surgical Clinics of North America. 2017;97(2):437–52. doi:10.1016/j.suc.2016.12.001.CrossRefPubMed

Bannon AE, Klug LR, Corless CL, Heinrich MC. Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. Expert Review of Molecular Diagnostics. 2017;17(5):445–57. doi:10.1080/14737159.2017.1308826.CrossRefPubMed

DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of surgery. 2000;231(1):51–8.CrossRefPubMedPubMedCentral

Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G et al. FGFR1 and NTRK3 actionable alterations in “wild-type” gastrointestinal stromal tumors. Journal of Translational Medicine. 2016;14(1):339. doi:10.1186/s12967-016-1075-6.CrossRefPubMedPubMedCentral

Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Archives of Pathology & Laboratory Medicine. 2006;130(10):1466–78.

Fero KE, Coe TM, Fanta PT, Tang CM, Murphy JD, Sicklick JK. Surgical management of adolescents and young adults with gastrointestinal stromal tumors: a US population-based analysis. JAMA Surgery. 2017. doi:10.1001/jamasurg.2016.5047.

Gold JS, Gonen M, Gutierrez A, Broto JM, Garcia-del-Muro X, Smyrk TC et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. The Lancet Oncology. 2009;10(11):1045–52. doi:10.1016/S1470-2045(09)70242-6.CrossRefPubMedPubMedCentral

Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. The Lancet Oncology. 2012;13(3):265–74. doi:10.1016/S1470-2045(11)70299-6.CrossRefPubMed

10.

Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2015;33(6):634–42. doi:10.1200/JCO.2014.57.4970.CrossRef

11.

Sicklick JK, Lopez NE. Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract. 2013;17(11):1997–2006. doi:10.1007/s11605-013-2243-0.CrossRef

12.

Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. The New England Journal of Medicine. 2001;344(14):1052–6. doi:10.1056/NEJM200104053441404.CrossRefPubMed

13.

Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–104. 10.1016/S0140-6736(09)60500-6.CrossRefPubMedPubMedCentral

14.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA : the Journal of the American Medical Association. 2012;307(12):1265–72. doi:10.1001/jama.2012.347.CrossRefPubMed

15.

Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD, Knowledge N. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153–63. doi:10.1530/ERC-13-0125.CrossRefPubMed

16.

Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12(2):153–72.CrossRefPubMed

17.

Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbeck’s Archives of Surgery/Deutsche Gesellschaft fur Chirurgie. 2011;396(3):299–311. doi:10.1007/s00423-011-0741-7.CrossRef

18.

Rindi G, Petrone G, Inzani F. 25 years of neuroendocrine neoplasms of the gastrointestinal tract. Endocr Pathol. 2014;25(1):59–64. doi:10.1007/s12022-013-9292-5.CrossRefPubMed

19.

Corey B, Chen H. Neuroendocrine tumors of the stomach. The Surgical Clinics of North America. 2017;97(2):333–43. doi:10.1016/j.suc.2016.11.008.CrossRefPubMed

20.

Jenny HE, Ogando PA, Fujitani K, Warner RR, Divino CM. Laparoscopic antrectomy: a safe and definitive treatment in managing type 1 gastric carcinoids. American Journal of Surgery. 2016;211(4):778–82. doi:10.1016/j.amjsurg.2015.08.040.CrossRefPubMed

21.

Postlewait LM, Baptiste GG, Ethun CG, Le N, Cardona K, Russell MC et al. A 15-year experience with gastric neuroendocrine tumors: does type make a difference? Journal of Surgical Oncology. 2016;114(5):576–80. doi:10.1002/jso.24369.CrossRefPubMed

22.

Mulkeen A, Cha C. Gastric carcinoid. Curr Opin Oncol. 2005;17(1):1–6.CrossRefPubMed

23.

Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology. 2006;84(3):158–64. doi:10.1159/000098007.CrossRefPubMed

24.

Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA, Jr., Norton JA. Lethality of multiple endocrine neoplasia type I. World J Surg. 1998;22(6):581–6; discussion 6-7.CrossRefPubMed

25.

Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14(23):7798–803. doi:10.1158/1078-0432.CCR-08-0734.CrossRefPubMed

26.

Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22(30):6817–28. doi:10.3748/wjg.v22.i30.6817.CrossRefPubMedPubMedCentral

27.

Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17(1):17–22. doi:10.1111/hpb.12225.CrossRef

28.

Delle Fave G, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach Best Practice & Research Clinical Gastroenterology. 2005;19(5):659–73. doi:10.1016/j.bpg.2005.05.002.CrossRef

29.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a Cancer Journal for Clinicians. 2015;65(2):87–108. doi:10.3322/caac.21262.

30.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a Cancer Journal for Clinicians. 2016;66(1):7–30. doi:10.3322/caac.21332.

31.

Ilson DH. Current progress in the adjuvant treatment of gastric cancer. Surgical Oncology Clinics of North America. 2017;26(2):225–39. doi:10.1016/j.soc.2016.10.008.CrossRefPubMed

32.

Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015;64(11):1721–31. doi:10.1136/gutjnl-2014-308252.CrossRefPubMed

33.

Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet Oncology. 2010;11(5):439–49. doi:10.1016/S1470-2045(10)70070-X.CrossRefPubMed

34.

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England Journal of Medicine. 2006;355(1):11–20. doi:10.1056/NEJMoa055531.CrossRefPubMed

35.

Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(13):1715–21. doi:10.1200/JCO.2010.33.0597.CrossRef

36.

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. The Lancet Oncology. 2016;17(12):1697–708. doi:10.1016/S1470-2045(16)30531-9.CrossRefPubMed

37.

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(33):4387–93. doi:10.1200/JCO.2011.36.5908.CrossRef

38.

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21. doi:10.1016/S0140-6736(11)61873-4.CrossRefPubMed

39.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. doi:10.1016/S0140-6736(10)61121-X.CrossRefPubMed

40.

Lynch HT, Grady W, Suriano G, Huntsman D. Gastric cancer: new genetic developments. Journal of Surgical Oncology. 2005;90(3):114–33; discussion 33. doi:10.1002/jso.20214.CrossRefPubMed

41.

Hebbard PC, Macmillan A, Huntsman D, Kaurah P, Carneiro F, Wen X et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Annals of Surgical Oncology. 2009;16(7):1890–5. doi:10.1245/s10434-009-0471-z.CrossRefPubMed

42.

Chen Y, Kingham K, Ford JM, Rosing J, Van Dam J, Jeffrey RB et al. A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Annals of Surgical Oncology. 2011;18(9):2594–8. doi:10.1245/s10434-011-1648-9.CrossRefPubMed

43.

Bardram L, Hansen TV, Gerdes AM, Timshel S, Friis-Hansen L, Federspiel B. Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations-a clinical observational study. Familial Cancer. 2014;13(2):231–42. doi:10.1007/s10689-013-9698-8.CrossRefPubMed

44.

Worster E, Liu X, Richardson S, Hardwick RH, Dwerryhouse S, Caldas C et al. The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. Annals of Surgery. 2014;260(1):87–93. doi:10.1097/SLA.0000000000000446.CrossRefPubMed

45.

Benusiglio PR, Malka D, Rouleau E, De Pauw A, Buecher B, Nogues C et al. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. Journal of Medical Genetics. 2013;50(7):486–9. doi:10.1136/jmedgenet-2012-101472.CrossRefPubMed

46.

Kelly KJ, Selby L, Chou JF, Dukleska K, Capanu M, Coit DG et al. Laparoscopic versus open gastrectomy for gastric adenocarcinoma in the west: a case-control study. Annals of Surgical Oncology. 2015;22(11):3590–6. doi:10.1245/s10434-015-4381-y.CrossRefPubMedPubMedCentral

47.

Huscher CG, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, Recher A et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Annals of Surgery. 2005;241(2):232–7.CrossRefPubMedPubMedCentral

48.

Vinuela EF, Gonen M, Brennan MF, Coit DG, Strong VE. Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Annals of Surgery. 2012;255(3):446–56. doi:10.1097/SLA.0b013e31824682f4.CrossRefPubMed

49.

Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. Journal of Surgical Oncology. 2013;107(3):230–6. doi:10.1002/jso.23262.CrossRefPubMed

50.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a Cancer Journal for Clinicians. 2011;61(2):69–90. doi:10.3322/caac.20107.

51.

Hamner J, Kim J. Surgery for cancers of the gastrointestinal tract. New York, NY: Springer-Verlag; 2014. p. 75–86.

52.

Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer. 1988;61(2):232–7.CrossRefPubMed

53.

Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1125 procedures. Journal of Surgical Oncology 2016;113(7):796–803. doi:10.1002/jso.24248.CrossRefPubMed

54.

Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Annals of Surgical Oncology. 2011;18(6):1575–81. doi:10.1245/s10434-011-1631-5.CrossRefPubMedPubMedCentral

55.

Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. Journal of Surgical Oncology. 2014;110(3):275–84. doi:10.1002/jso.23633.CrossRefPubMed

56.

Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Annals of Surgical Oncology. 2016;23(6):1971–9. doi:10.1245/s10434-015-5081-3.CrossRefPubMed

Titel: SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors
verfasst von: Jeffrey A. Norton
Teresa Kim
Joseph Kim
Martin D. McCarter
Kaitlyn J. Kelly
Joyce Wong
Jason K. Sicklick
Publikationsdatum: 14.08.2017
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Surgery / Ausgabe 1/2018
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-017-3533-8

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Updates and Critical Insights on Glissonian Approach in Liver Surgery

Muzi’s Tension Free Primary Closure of Pilonidal Sinus Disease: Updates on Long-Term Results on 514 Patients

Better Late than Never? Adherence to Adjuvant Therapy Guidelines for Stage III Colon Cancer in an Underserved Region

Is pH Testing Necessary Before Antireflux Surgery in Patients with Endoscopic Erosive Esophagitis?

Paraneoplastic Stiff Person Syndrome Secondary to Pancreatic Adenocarcinoma

Accuracy of Various Lymph Node Staging Criteria in Rectal Cancer with Magnetic Resonance Imaging

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“